IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy
Huang, Xiaojun1; Wang, Fengrong1; Chen, Yuhong1; Liu, Ting2; Wang, Jianxiang3,4,5; Hu, Jianda6; Jie, Jin7; Chen, Fangping8; Wang, Shujie9; Shen, Zhixiang10; Yu, Li11; Yu, Kang12; Liang, Yingmin13
关键词efficacy invasive fungal infection posaconazole
刊名FUTURE MICROBIOLOGY
2012-02-01
DOI10.2217/FMB.11.158
7期:2页:201-209
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Microbiology
研究领域[WOS]Microbiology
关键词[WOS]AMPHOTERICIN-B ; ANTIFUNGAL AGENTS ; ASPERGILLOSIS ; RESISTANCE ; SPECTRUM
英文摘要

Aim: Invasive fungal infections pose a severe health threat to patients. Despite recent advances in drug development, treatment of recurrent fungal infections remains difficult. Posaconazole is a broad-spectrum triazole antifungal drug available for oral administration. Although initial studies have described its use in treating various fungal infections, its efficacy and safety in patients with invasive fungal infections remains to be further confirmed. Materials & Methods: In this study, we performed a multicenter, open-label clinical trial of posaconazole oral suspension in the treatment of 63 patients with invasive fungal infections who were refractory to or intolerant of first-line therapy. Results: Our result showed that 64.4% of patients had a clinical response after posaconazole treatment, with 52.9% showing eradication of the fungal infection. The treatment caused some adverse effects of mild or moderate severity that were of short duration. Conclusion: The results of this trial indicate that posaconazole can be used in invasive fungal infections as an alternative or salvage therapy.

语种英语
WOS记录号WOS:000300277900010
资助机构Merck &amp ; Co., Inc., Whitehouse Station, NJ, USA
引用统计
被引频次:8[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/63990
专题北京大学第二临床医学院_血液科
作者单位1.Peking Univ, Inst Hematol, Peoples Hosp, Beijing 100871, Peoples R China
2.Sichuan Univ, Huaxi Hosp, Chengdu 610064, Peoples R China
3.Chinese Acad Med Sci, Inst Hematol, Tianjin, Peoples R China
4.Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China
5.Peking Union Med Coll, Tianjin, Peoples R China
6.Fujian Med Univ, Union Hosp, Fuzhou, Fujian, Peoples R China
7.Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China
8.Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China
9.Wenzhou Med Coll, Wenzhou, Zhejiang, Peoples R China
10.Beijing Union Med Coll Hosp, Beijing 100730, Peoples R China
11.Shanghai Jiao Tong Univ, Rui Jin Hosp, Sch Med, Shanghai 200030, Peoples R China
12.Chinese Peoples Liberat Army, Gen Hosp, Beijing, Peoples R China
13.Fourth Mil Med Univ Xian, Tangdu Hosp, Xian, Peoples R China
推荐引用方式
GB/T 7714
Huang, Xiaojun,Wang, Fengrong,Chen, Yuhong,et al. A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy[J]. FUTURE MICROBIOLOGY,2012,7(2):201-209.
APA Huang, Xiaojun.,Wang, Fengrong.,Chen, Yuhong.,Liu, Ting.,Wang, Jianxiang.,...&Liang, Yingmin.(2012).A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy.FUTURE MICROBIOLOGY,7(2),201-209.
MLA Huang, Xiaojun,et al."A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy".FUTURE MICROBIOLOGY 7.2(2012):201-209.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Huang, Xiaojun]的文章
[Wang, Fengrong]的文章
[Chen, Yuhong]的文章
百度学术
百度学术中相似的文章
[Huang, Xiaojun]的文章
[Wang, Fengrong]的文章
[Chen, Yuhong]的文章
必应学术
必应学术中相似的文章
[Huang, Xiaojun]的文章
[Wang, Fengrong]的文章
[Chen, Yuhong]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。